Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abivertinib - ACEA Therapeutics

Next Previous
Drug Profile

Abivertinib - ACEA Therapeutics

Alternative Names: A 610MA; Abivertinib maleate - ACEA Therapeutics; AC 0100; AC 0100 Maleate; AC-0010MA; ACEA-100610MA; Avitinib maleate - ACEA Therapeutics; EX-ACEA-0010MA; Fujovee; STI-5656

Latest Information Update: 12 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACEA Therapeutics
  • Developer ACEA Biosciences; ACEA Therapeutics; Guangdong Provincial Peoples Hospital; Hangzhou ACEA Pharmaceutical Research; Sorrento Therapeutics
  • Class Acrylamides; Antineoplastics; Antivirals; Fluorobenzenes; Heterocyclic compounds; Piperazines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; ErbB receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer
  • Phase II COVID 2019 infections; Marginal zone B-cell lymphoma; Prostate cancer

Most Recent Events

  • 12 Aug 2026 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in Spain (PO) (ACEA Therapeutics Pipeline, August 2026)
  • 12 Aug 2026 Phase-III clinical trials in Non-small cell lung cancer in USA (PO) (ACEA Therapeutics pipeline, August 2026)
  • 11 Aug 2026 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in France (PO) (ACEA Therapeutics Pipeline, August 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top